Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: A systematic review and meta-analysis

Scientific World Journal

Volumn 2015, Issue , 2015, Pages

  Choi, Yun Jung ^a  

^a Chung Ang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FAMOTIDINE; FLUOXETINE; METFORMIN; NIZATIDINE; OLANZAPINE; PLACEBO; REBOXETINE; SIBUTRAMINE; TOPIRAMATE; ANTIOBESITY AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; AUDITORY HALLUCINATION; BRIEF PSYCHIATRIC RATING SCALE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; OBESITY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SINUS TACHYCARDIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL; WEIGHT REDUCTION; COMBINATION DRUG THERAPY; COMPLICATION; PSYCHOLOGY;

ANTI-OBESITY AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; OBESITY; SCHIZOPHRENIA;

EID: 84947648635     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2015/970730     Document Type: Review

References (33)

1. E. Levy, C. Agbokou, F. Ferreri, G. Chouinard, and H. C. Margolese, "Topiramate-induced weight loss in schizophrenia: a retrospective case series study" Canadian Journal of Clinical Pharmacology, vol. 14, no. 2, pp. e234-e239, 2007.
2. W. K. Kroeze, S. J.Hufeisen, B. A. Popadak et al., "H1-histamine receptor affinity predicts short-termweight gain for typical and atypical antipsychotic drugs" Neuropsychopharmacology, vol. 28, no. 3, pp. 519-526, 2003.
3. L. A. Templeman, G. P. Reynolds, B. Arranz, and L. San, "Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis" Pharmacogenetics and Genomics, vol. 15, no. 4, pp. 195-200, 2005.
4. L. Maayan, J. Vakhrusheva, and C. U. Correll, "Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and metaanalysis" Neuropsychopharmacology, vol. 35, no. 7, pp. 1520-1530, 2010.
5. S. Coodin, "Body mass index in persons with schizophrenia" Canadian Journal of Psychiatry, vol. 46,no. 6, pp. 549-555, 2001.
6. M. Muscatello, A. Bruno, G. Pandolfo et al., "Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study" Journal of Psychopharmacology, vol. 25, no. 5, pp. 667-674, 2011.
7. D. C. Henderson, X. Fan, P. M. Copeland et al., "A doubleblind, placebo-controlled trial of sibutramine for olanzapineassociated weight gain" The American Journal of Psychiatry, vol. 162, no. 5, pp. 954-962, 2005.
8. W. W. Fleischhacker, M. E. Heikkinen, J.-P. Olie et al., "Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial" International Journal of Neuropsychopharmacology, vol. 13, no. 8, pp. 1115-1125, 2010.
9. P. K. Narula, H. S. Rehan, K. E. S. Unni, and N. Gupta, "Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a doubleblind, placebo-controlled trial" Schizophrenia Research, vol. 118, no. 1-3, pp. 218-223, 2010.
10. H. Afshar, H. Roohafza, G. Mousavi et al., "Topiramate addon treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial" Journal of Psychopharmacology, vol. 23, no. 2, pp. 157-162, 2009.
11. T. Baptista, E.Uzcategui,N. Rangel et al., "Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebocontrolled pilot study" Psychiatry Research, vol. 159, no. 1-2, pp. 250-253, 2008.
12. R.-R. Wu, J.-P. Zhao, X.-F. Guo et al., "Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebocontrolled study" The American Journal of Psychiatry, vol. 165, no. 3, pp. 352-358, 2008.
13. T. Baptista, N. Rangel, V. Fernandez et al., "Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial" Schizophrenia Research, vol. 93, no. 1-3, pp. 99-108, 2007.
14. D. C.Henderson, X. Fan, P. M. Copeland et al., "A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain" Acta Psychiatrica Scandinavica, vol. 115, no. 2, pp. 101-105, 2007.
15. M. Poyurovsky, C. Fuchs, A. Pashinian et al., "Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study" Psychopharmacology, vol. 192, no. 3, pp. 441-448, 2007.
16. T. Baptista, J. Martinez, A. Lacruz et al., "Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial" Canadian Journal of Psychiatry, vol. 51, no. 3, pp. 192-196, 2006.
17. M. Poyurovsky, V. Tal, R. Maayan, I. Gil-Ad, C. Fuchs, and A. Weizman, "The effect of famotidine addition on olanzapineinduced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study" European Neuropsychopharmacology, vol. 14, no. 4, pp. 332-336, 2004.
18. P. Cavazzoni, Y. Tanaka, S. M. Roychowdhury, A. Breier, and D. B. Allison, "Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial" European Neuropsychopharmacology, vol. 13, no. 2, pp. 81-85, 2003.
19. M. Poyurovsky, I. Isaacs, C. Fuchs et al., "Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study" American Journal of Psychiatry, vol. 160, no. 2, pp. 297-302, 2003.
20. M. Poyurovsky, A. Pashinian, I. Gil-Ad et al., "Olanzapineinduced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition" The American Journal of Psychiatry, vol. 159, no. 6, pp. 1058-1060, 2002.
21. A. Bertani, G. Perna, G. Migliarese et al., "Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study" Pharmacopsychiatry, vol. 37, no. 5, pp. 206-210, 2004.
22. T. Y.-T. Lu, A. Kupa, G. Easterbrook, and A. A. Mangoni, "Profound weight loss associated with reboxetine use in a 44-year-old woman" British Journal of Clinical Pharmacology, vol. 60, no. 2, pp. 218-220, 2005.
23. M. Poyurovsky, S. Faragian, C. Fuchs, and A. Pashinian, "Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an addon, double-blind placebo-controlled study" The Israel Journal of Psychiatry and Related Sciences, vol. 46, no. 3, pp. 213-220, 2009.
24. L. Radulovic, P. Weiden, and D. B. Allison, "A double-blind, placebocontrolled trial of adjunctive sibutramine for obesity in patients with schizophrenia" in Proceedings of the Meeting of the New Clinical Drug Evaluation Unit (NCDEU 02), pp. 1-15, Rockville, Md, USA, 2002.
25. A. J. Scheen, "Sibutramine on cardiovascular outcome" Diabetes Care, vol. 34, no. 2, pp. S114-S119, 2011.
26. S.K.Praharaj, A. K. Jana,N.Goyal, andV. K. Sinha, "Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis" British Journal of Clinical Pharmacology, vol. 71, no. 3, pp. 377-382, 2011.
27. R. L. Kolotkin, P. K. Corey-Lisle, R. D. Crosby, H. J. Kan, and R. D.McQuade, "Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care" European Psychiatry, vol. 23, no. 8, pp. 561-566, 2008.
28. J.W. Newcomer, J. A. Campos, R. N.Marcus et al., "Amulticenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine" The Journal of Clinical Psychiatry, vol. 69, no. 7, pp. 1046-1056, 2008.
29. K. Karunakaran, T. E. Tungaraza, and G. C. Harborne, "Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?" Journal of Psychopharmacology, vol. 21, no. 4, pp. 453-456, 2007.
30. D. C. Henderson, X. Fan, P. M. Copeland et al., "Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients" Journal ofClinical Psychopharmacology, vol. 29,no. 2, pp. 165-169, 2009.
31. E. Ben-Menachem, M. Axelsen, E. H. Johanson, A. Stagge, and U. Smith, "Predictors of weight loss in adults with topiramatetreated epilepsy" Obesity Research, vol. 11, no. 4, pp. 556-562, 2003.
32. G. Gobbi, P.-O. Gaudreau, and N. Leblanc, "Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis" Journal of Clinical Psychopharmacology, vol. 26, no. 5, pp. 467-473, 2006.
33. M. K. Hahn, G. Remington, D. Bois, and T. Cohn, "Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects" Journal of Clinical Psychopharmacology, vol. 30, no. 6, pp. 706-710, 2010.